Literature DB >> 22971034

Meaningful change in oncology quality-of-life instruments: a systematic literature review.

Gillian Bedard1, Liang Zeng, Henry Lam, David Cella, Liying Zhang, Natalie Lauzon, Edward Chow.   

Abstract

Quality of life (QoL) is increasingly being recognized as an important end point in oncology clinical trials. The purpose of this study was to review the literature on what constitutes a meaningful change in oncology QoL instruments. A literature search was conducted in Medline, Embase, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. Articles determining clinically meaningful change were selected. Twenty six publications were identified. Common anchors included performance status, global rating of change and overall QoL. The distribution approach utilized standard deviations and standard error of measurement. Limitations included optimism bias and a change in patients' internal frame of reference. Currently, there is an inconsistency between meaningful change studies. Analyses should be conducted in population-specific samples, as meaningful change varies depending on patient characteristics. Consistently, meaningful change for improvement has been smaller than that for deterioration, suggesting that patients are more responsive to improvement.

Entities:  

Mesh:

Year:  2012        PMID: 22971034     DOI: 10.1586/erp.12.34

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  8 in total

1.  Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Authors:  C Quinten; C Kenis; L Decoster; P R Debruyne; I De Groof; C Focan; F Cornelis; V Verschaeve; C Bachmann; D Bron; S Luce; G Debugne; H Van den Bulck; J C Goeminne; A Baitar; K Geboers; B Petit; C Langenaeken; R Van Rijswijk; P Specenier; G Jerusalem; J P Praet; K Vandenborre; M Lycke; J Flamaing; K Milisen; J P Lobelle; H Wildiers
Journal:  Qual Life Res       Date:  2018-12-03       Impact factor: 4.147

2.  Minimal clinically important differences in the brief pain inventory in patients with bone metastases.

Authors:  Karrie Wong; Liang Zeng; Liying Zhang; Gillian Bedard; Erin Wong; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal; Lori Holden; Natalie Lauzon; Edward Chow
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

3.  Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis.

Authors:  Vincenzo O Palmieri; Daniela Santovito; Francesco Margari; Madia Lozupone; Francesco Minerva; Carla Di Gennaro; Orlando Todarello; Giuseppe Palasciano
Journal:  Clin Exp Med       Date:  2013-12-10       Impact factor: 3.984

4.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 5.  Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

Authors:  Peter Johnson; Wolfgang Greiner; Imad Al-Dakkak; Samuel Wagner
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

6.  Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.

Authors:  Ingolf Griebsch; Michael Palmer; Peter M Fayers; Stuart Ellis
Journal:  BMJ Open       Date:  2014-10-31       Impact factor: 2.692

7.  Minimally important differences for Patient Reported Outcomes Measurement Information System pain interference for individuals with back pain.

Authors:  Dagmar Amtmann; Jiseon Kim; Hyewon Chung; Robert L Askew; Ryoungsun Park; Karon F Cook
Journal:  J Pain Res       Date:  2016-04-27       Impact factor: 3.133

8.  Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms.

Authors:  Robert Hettle; John Borrill; Gaurav Suri; Jerome Wulff
Journal:  Clinicoecon Outcomes Res       Date:  2015-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.